Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Free Report) CEO Robb Knie purchased 25,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $0.67 per share, with a total value of $16,750.00. Following the purchase, the chief executive officer now owns 58,131 shares in the company, valued at $38,947.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Hoth Therapeutics Stock Performance
Shares of HOTH opened at $0.68 on Wednesday. The firm has a market cap of $3.65 million, a price-to-earnings ratio of -0.35 and a beta of 0.80. Hoth Therapeutics, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $3.37. The firm has a 50 day moving average price of $0.82 and a 200-day moving average price of $1.11.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research note on Friday, August 16th.
About Hoth Therapeutics
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Read More
- Five stocks we like better than Hoth Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Which Wall Street Analysts are the Most Accurate?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Trading Halts Explained
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.